Norovirus GII.4 consensus major capsid protein VP1 (NoV GII.4c VP1)

Norovirus GII.4 consensus major capsid protein VP1 (GII.4c VP1) is an engineered viral protein designed to serve as a broad-spectrum immunogen in norovirus vaccines. As the primary structural component of the norovirus capsid, VP1 mediates host cell recognition and entry by binding to histo-blood group antigens (HBGAs) via its hypervariable P2 subdomain. The GII.4c variant is a synthetic consensus sequence derived from multiple dominant GII.4 strains—specifically the 2002 Houston, 2006a Yerseke, and 2006b Den Haag variants—to address the rapid antigenic drift of the GII.4 genotype, which causes the majority of global gastroenteritis outbreaks. In clinical development, GII.4c VP1 is typically expressed to form virus-like particles (VLPs) that mimic the native virus but lack the viral genome, making them safe for use as immunogens. Leading vaccine candidates, such as HIL-214 (formerly TAK-214), utilize this consensus protein to induce neutralizing antibodies that block the VP1-HBGA interaction, a key correlate of protection against infection. However, challenges remain, including the potential for GII.4c VP1 to assemble into T=4 symmetry particles rather than the native T=3 form, which may impact the presentation of neutralizing epitopes.

Other names

Norovirus GII.4c major capsid proteinGII.4 consensus VP1NoV GII.4c capsid proteinGII.4c VLPNorovirus GII.4c structural protein VP1

Active immunization to elicit neutralizing antibodies that block the interaction between the viral P2 domain and host histo-blood group antigens (HBGAs), thereby preventing viral attachment and entry.